🇺🇸 FDA
Patent

US 11566236

Materials and methods for treatment of hemoglobinopathies

granted A61KA61K31/395A61K31/712

Quick answer

US patent 11566236 (Materials and methods for treatment of hemoglobinopathies) held by Vertex Pharmaceuticals Incorporated expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/395, A61K31/712, A61K31/7125, A61K35/28